Last updated: February 21, 2026
What is the Drug and Its Indication?
NDC 66689-0305 is identified as Risdiplam (Evrysdi), a medication approved by the FDA for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. It is a liquid oral therapy that modifies disease progression by increasing SMN protein production.
Market Overview
Market Size and Demographics
- Prevalence of SMA: Estimated at approximately 1 in 10,000 live births globally, with about 1,200 to 2,000 cases diagnosed annually in the U.S.
- Patient Population: Approximate U.S. SMA population includes:
- Infants and children: 80%
- Adults with SMA: 20%
- Unmet Needs: Early diagnosis, broadening age indications, and long-term management.
Market Players
- Current Market Leaders:
- Spinraza (nusinersen)—Biogen
- Zolgensma (onasemnogene abeparvovec)—Novartis
- Market Entry Timing:
- Evrysdi was launched in 2020.
- Spinraza launched in 2016, Zolgensma in 2019.
Competition and Market Dynamics
-
Pricing Strategies
- Spinraza: ~$125,000 per injection, with a typical dosing schedule of 4 doses in the first year.
- Zolgensma: Single-dose gene therapy, priced at approximately $2.1 million per treatment.
- Evrysdi: Priced at ~$34,000 annually.
-
Market Penetration
- Evrysdi has gained rapid adoption due to its oral administration, patient convenience, and comparable efficacy.
- Coverage expansion and reimbursement policies influence market growth.
Price Projections
Current Pricing and Revenue
| Drug |
Price / Year |
Mode of Administration |
Market Share (2022) |
Estimated U.S. Revenue (2022) |
| Evrysdi |
~$34,000 |
Oral liquid |
25% |
~$300 million |
| Spinraza |
~$125,000 / injection |
Intrathecal injection |
55% |
~$1.2 billion |
| Zolgensma |
~$2.1 million |
Intravenous, single dose |
20% |
~$500 million |
Future Price Trends
- Pricing strategies are expected to stabilize owing to existing reimbursement frameworks, but slight increases could occur as newer indications expand.
- Potential discounts or value-based pricing may be introduced to improve access and influence revenue.
Revenue Projections (2023-2027)
| Year |
Estimated Market Size (Patients) |
Total Market Revenue |
Evrysdi Market Share (Projected) |
Evrysdi Revenue |
| 2023 |
4,000 |
~$2.4 billion |
30% |
~$720 million |
| 2024 |
4,500 |
~$2.7 billion |
35% |
~$945 million |
| 2025 |
5,000 |
~$3.0 billion |
40% |
~$1.2 billion |
| 2026 |
5,500 |
~$3.3 billion |
45% |
~$1.5 billion |
| 2027 |
6,000 |
~$3.6 billion |
50% |
~$1.8 billion |
Assumptions: Continued expansion of indications, increased market penetration, and stable pricing.
Risks and Challenges
- Pricing pressure from insurers and payers.
- Market saturation once most eligible patients are treated.
- Emergence of biosimilars or generics if patent protections change.
Key Takeaways
- NDC 66689-0305 (Risdiplam) captures approximately 25% of the SMA treatment market as of 2022.
- Its oral route gives it a competitive edge over injectable therapies, facilitating growth.
- Revenue projections show potential for approximately $1.8 billion in U.S. annual sales by 2027, assuming market share increases.
- Pricing is expected to remain relatively stable, with modest adjustments influenced by market dynamics and reimbursement policies.
- Competition from existing therapies, especially Zolgensma's one-time high-cost treatment, will continue to shape market strategies.
FAQs
1. What factors could influence Risdiplam’s future pricing?
Reimbursement negotiations, competitive pressures, regulatory changes, and advancements in SMA therapeutics could impact pricing strategies.
2. How does Risdiplam’s market share compare to Zolgensma and Spinraza?
It has a smaller market share but benefits from easier administration and expanding indications—projected to grow from 25% in 2022 to around 50% in 2027.
3. Are there any upcoming patent expirations for Risdiplam?
Patent protections are expected to last until 2030, with potential for patent extensions or formulation patents preventing generic entry beforehand.
4. How do pricing differences impact patient access?
Lower annual costs improve affordability and insurance coverage. Oral administration reduces barriers associated with injections.
5. What are the key opportunities for market expansion?
Broader age indications, increased diagnosis rates, and improved healthcare provider adoption could drive further sales growth.
References
[1] U.S. Food and Drug Administration (FDA). (2020). Evrysdi (risdiplam) approval letter.
[2] IQVIA. (2022). Pharmaceutical Market Dynamics.
[3] EvaluatePharma. (2022). SMN Therapeutics Market Report.
[4] Centers for Disease Control and Prevention (CDC). (2021). Spinal Muscle Atrophy Statistics.
[5] BioPharm Insight. (2023). Pricing Trends in Rare Disease Therapies.
